ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
ASH 2025 – BeOne pulls away from Nurix
On efficacy, at least, BeOne’s BTK degrader shows an edge.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
ESMO Asia 2025 – Oric’s first-line gamble
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
